**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 49448**

**Manuscript Type: REVIEW**

**Gut-liver axis signaling in portal hypertension**

Simbrunner B *et al.* Gut-liver axis signaling in PHT

Benedikt Simbrunner, Mattias Mandorfer, Michael Trauner, Thomas Reiberger

**Benedikt Simbrunner, Mattias Mandorfer, Michael Trauner, Thomas Reiberger,** Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna 1180, Austria

**Benedikt Simbrunner, Mattias Mandorfer, Thomas Reiberger,** Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna 1180, Austria

**ORCID number:** Benedikt Simbrunner (0000-0001-8181-9146); Mattias Mandorfer (0000-0003-2330-0017); Michael Trauner (0000-0002-1275-6425); Thomas Reiberger (0000-0002-4590-3583).

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No financial support has been received for this review. Benedikt Simbrunner has received travel support from AbbVie and Gilead; Mattias Mandorfer has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W.L. Gore & Associates and Janssen; Michael Trauner received speaker fees from BMS, Falk Foundation, Gilead and MSD; advisory board fees from Albireo, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. Thomas Reiberger received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited Manuscript

**Corresponding author:** **Thomas Reiberger, MD, Associate Professor, Doctor,** Division of Gastroenterology and Hepatology, Department of Internal Medicine III,

Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1180, Austria. thomas. reiberger@meduniwien.ac.at

**Telephone:** +43-1-4040065890

**Fax:** +43-1-4040047350

**Received:** June 4, 2019

**Peer-review started:** June 4, 2019

**First decision:** July 21, 2019

**Revised:** August 15, 2019

**Accepted:** September 27, 2019

**Article in press:**

**Published online:**

**Abstract**

Portal hypertension (PHT) in advanced chronic liver disease (ACLD) results from increased intrahepatic resistance caused by pathologic changes of tissue composition (structural component) and intrahepatic vasoconstriction (functional component). PHT is an important driver of hepatic decompensation such as development of ascites or variceal bleeding. Dysbiosis and an impaired intestinal barrier in ACLD facilitate translocation of bacteria and pathogen-associated molecular patterns that promote disease progression *via* immune system activation with subsequent induction of proinflammatory and profibrogenic pathways. One decisive pathophysiological mechanism linking PHT to increased intestinal permeability lies in the congestive portal venous blood flow: The intestinal barrier function is affected by impaired microcirculation, neoangiogenesis, and abnormal vascular and mucosal permeability. The close bidirectional relationship between the gut and the liver has been termed “gut-liver axis”. Treatment strategies targeting the gut-liver axis *via* modulation of microbiota composition and function, intestinal barrier integrity, as well as amelioration of liver fibrosis and PHT, are supposed to exert beneficial effects. The activation of the farnesoid X receptor in the liver and the gut and associated fibroblast growth factor 19 signaling have shown promising results in animal experiments, however, further studies regarding efficacy and safety in humans with ACLD are needed. In this review, we summarize the clinical impact of PHT on the course of liver disease, discuss pathophysiological mechanisms that link PHT to gut-liver axis signaling, and provide insight into molecular mechanisms that may represent novel therapeutic targets.

**Key words:** Cirrhosis; Portal hypertension; Gut-liver axis; Bacterial translocation; Intestinal barrier; Farnesoid X receptor

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In advanced chronic liver disease, portal hypertension (PHT) results from increased intrahepatic resistance and leads to splanchnic vasodilation and neovascularization in the intestines. Gut dysbiosis, increased intestinal permeability, translocation of bacteria and pathogen-associated molecular patterns can further promote liver disease progression, often mediated *via* immune system activation and a subsequent induction of a proinflammatory state. The close relationship between gut and liver and their bidirectional interaction has been termed gut-liver axis. This review aims to connect the impact of PHT on the gut-liver axis by providing both insight into pathophysiology and clinical observations, as well as therapeutic strategies.

Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Advanced chronic liver disease (ACLD)/cirrhosis represents a significant health burden, accounting for considerable morbidity and mortality worldwide[[1](#_ENREF_1)]. Cirrhosis was found responsible for about 1.0 million deaths in 2010[[2](#_ENREF_2)] and for 1.2 million deaths in 2013[[3](#_ENREF_3)], indicating an increasing trend over the years. Recent epidemiological data from Europe displays heterogeneity regarding prevalence, etiology, and mortality trends in different European countries and suggests that public health action and prudent treatment strategies might exert considerable public health benefits[[4](#_ENREF_4)].

The clinical course of ACLD can be divided in a compensated and decompensated stage[[5](#_ENREF_5),[6](#_ENREF_6)]. The compensated stage may last for several years[[5](#_ENREF_5)], while the development of typical complications of cirrhosis, *i.e.* most commonly ascites but also variceal hemorrhage or hepatic encephalopathy [*i.e.*, acute decompensation (AD)] defines the progression to the decompensated stage. Furthermore, patients with ACLD are at risk for developing organ failures, *i.e.* acute-on-chronic liver failure (ACLF), a syndrome which is associated with a high risk of mortality[[7-11](#_ENREF_7)].

The development of portal hypertension (PHT) holds a central role in the progression of liver disease, as it drives hepatic decompensation and other complications of cirrhosis[[5](#_ENREF_5),[12](#_ENREF_12)]. Based on a body of evidence propagating an impact of gut microbiota, intestinal barrier integrity, and bacterial translocation (BT) on the course of liver disease, the term “gut-liver axis” has arisen over the last few years, subsuming the close relationship between the gut and the liver in different entities of ACLD[[13-15](#_ENREF_13)]. BT (migration from intestinal bacteria and/or their products beyond the intestinal barrier) impacts on the course of disease in cirrhosis by promoting/precipitating AD, ACLF, and finally, mortality. Hence, the gut-liver axis has gained considerable scientific interest[[5](#_ENREF_5),[16](#_ENREF_16),[17](#_ENREF_17)]. The aim of this review is to summarize current knowledge on pathophysiological links between gut-liver axis signaling and PHT, and to provide additional insights into the effects of established and investigational therapeutic approaches. The search strategy and selection criteria of this study are shown in Supplemental materials.

**PHT AND IMMUNE SYSTEM ACTIVATION**

***PHT and BT are linked to clinical events***

Characteristic histological features of cirrhosis include diffuse nodular regeneration enclosed by fibrotic septa, leading to parenchymal loss-of-function and destruction of liver structure, caused by necroinflammation and fibrogenesis due to ACLD[[18-20](#_ENREF_18)]. These structural changes deteriorate the vascular (sinusoidal) architecture and promote intrahepatic vasoconstriction, which leads to an increase in intrahepatic resistance[[20-22](#_ENREF_20)]. Along with progressive increases of portal blood flow, the elevated intrahepatic resistance leads to the development of PHT[[20](#_ENREF_20),[21](#_ENREF_21)]. The measurement of the hepatic venous pressure gradient (HVPG) is the gold standard for assessing sinusoidal PHT with a HVPG ≥ 10 mmHg defining clinically significant PHT (CSPH)[[20](#_ENREF_20),[23](#_ENREF_23)]. The formation of portosystemic collaterals (*e.g.*, varices), as well as clinical events that define hepatic decompensation and hepatocellular carcinoma (HCC) development are strongly associated with CSPH[[20](#_ENREF_20),[23](#_ENREF_23),[24](#_ENREF_24)].

Importantly, the portal vein is anatomically linked to the venous blood flow drained from splanchnic organs and the intestines. While subclinical PHT is primarily due to increased intrahepatic resistance, the development of hyperdynamic circulation in patients with CSPH[[25](#_ENREF_25),[26](#_ENREF_26)] further deteriorates PHT. Hyperdynamic circulation emerges from splanchnic vasodilation caused by an increased release of vasodilating molecules and a decreased responsiveness to vasoconstrictors. However, at which stage the mucosal barrier is affected by PHT, and thus, propagates BT and PHT, remains unclear. Still BT is believed to promote liver disease progression and aggravate splanchnic vasodilation in PHT[[12](#_ENREF_12)].

The reduced effective circulating blood volume resulting from splanchnic pooling induces a vicious circle *via* activation of compensatory measures, such as the sympathetic nervous and renin-angiotensin-aldosteron systems. These mechanisms aim to increase circulating blood volume to ensure adequate organ perfusion[[12](#_ENREF_12),[27](#_ENREF_27),[28](#_ENREF_28)]. This state is characterized by an increment of heart rate and cardiac output as well as decreased systemic vascular resistance[[21](#_ENREF_21),[29](#_ENREF_29)]. In turn, portal venous inflow increases and further exacerbates PHT[[25](#_ENREF_25)].

***Pathophysiological background on inflammation and BT***

The identification of Toll-like receptor (TLR) involvement in gut-liver-signaling has provided important evidence for the link between inflammation and innate immunity in ACLD. TLRs are mammalian analogues of pattern-recognition receptors and capable of recognizing pathogens or pathogen-associated molecular patterns (PAMPs)[[30](#_ENREF_30)]. PAMPs are products of microbial metabolism that are specifically produced by pathogens and not by the host[[31](#_ENREF_31)]. The term comprises different molecule types, such as lipids and nucleic acids[[32](#_ENREF_32)]. Some TLRs recognize a diverse structural spectrum of ligands. For example, TLR4 recognizes lipopolysaccharide (LPS), heat-shock proteins, fibronectin, or specific virus envelope proteins[[32](#_ENREF_32)]. In addition to PAMPs, TLRs also recognize danger-associated molecular patterns (DAMPs) that originate from apoptotic cells[[17](#_ENREF_17)].

TLRs are expressed in immune cells but also in epithelial cells and fibroblasts, and different TLR subtypes are expressed in divers cellular compartments[[32](#_ENREF_32)]. Recognition of PAMPs by TLRs usually results in activation of an inflammatory pathway signaling cascade that initiates upregulation of several genes encoding for inflammatory cytokines, chemokines and acute phase proteins[[17](#_ENREF_17),[33](#_ENREF_33)]. While in principal, this response mechanism is indispensable for protection against pathogens, exaggerated or sustained activation may cause functional and morphological alterations (*e.g.* *via* apoptotic and pro-fibrotic pathways) and induce a compensatory reduction of immune system activity upon chronic activation (*e.g.* *via* IL-10 or soluble cytokine receptors), thus, promoting susceptibility to infections[[33](#_ENREF_33),[34](#_ENREF_34)]. For example, chronic exposure to LPS can induce endotoxin tolerance by TLR4 dependent pathways, which is characterized by dampened antigen presentation, reduction of proinflammatory mediators and overexpression of anti-inflammatory signaling molecules[[35](#_ENREF_35)].

***Gut-liver crosstalk influences immune system homeostasis***

The portal venous system transports nutrients and gut-derived signaling molecules as well as pathogens or PAMPs/DAMPs to the liver[[36](#_ENREF_36)]. ACLD is associated with systemic proinflammatory changes that are clinically represented by elevated levels of C-reactive protein, inflammatory cytokines and immune cell activation markers[[37](#_ENREF_37),[38](#_ENREF_38)]. Different hepatic cells interact by either producing or reacting to inflammatory cytokines. The equilibrium of pro-inflammatory *vs* anti-inflammatory cytokines may shift the course of disease towards progression or regeneration in patients with liver disease[[39](#_ENREF_39)].

Systemic inflammation in patients with ACLD as compared to healthy subjects is considered to be caused by translocation of pathogens (or derived PAMPs and DAMPs) into the portal and systemic circulation *via* an impaired intestinal barrier, especially in the presence of intestinal dysbiosis[[15](#_ENREF_15)]. The physiological slow blood flow in liver sinusoids enables a close and thorough interaction of gut-derived molecules with hepatic non-parenchymal and parenchymal cells, and importantly, also with immune cells[[40](#_ENREF_40)]. Additionally, fenestrations within the sinusoidal endothelium between liver sinusoidal endothelial cells (LSECs) facilitate extravasation of molecules and migration of immune cells[[40](#_ENREF_40)]. Induction of the inflammasome (*i.e.* mediators of inflammatory response by upregulation of cytokines and caspases upon innate immune system recognition of PAMPs and DAMPs) *via* these mechanisms are associated with profibrotic and proinflammatory signaling cascades that putatively contribute to further aggravation of acute and chronic liver disease[[41-43](#_ENREF_41)].

Hepatic immune cells “communicate” the presence of BT and liver injury to other cell types *via* activation of inflammatory and profibrotic pathways[[44](#_ENREF_44)]. For instance, Kupffer cells, the liver-specific resident macrophages produce cytokines and chemotactic molecules in response to liver injury. As a result, additional monocyte-derived macrophages, but also natural killer and natural killer T cells are recruited to the liver[[45](#_ENREF_45)]. Recognition of LPS by TLR4 on these macrophages and Kupffer cells results in activation of the NFκ-B-regulated inflammasome and increased Tumor necrosis factor (TNF) -α synthesis[[46](#_ENREF_46)]. In the continuous presence of injury, DAMPs and/or PAMPs, these cells create a proinflammatory environment that finally facilitates hepatocyte injury, fibrosis *via* hepatic stellate cell activation, and even promotes tumor development[[44](#_ENREF_44),[45](#_ENREF_45)].

For example, alcohol intake is associated with translocating PAMPs and microbiome changes that induce inflammatory signaling pathways in the liver and intestines[[46-50](#_ENREF_46)]. Alcohol exposure also impacts on the expression profile of cytokines produced by intestinal immune cells (*e.g.* TNF-α and IL-1β) that impact both on liver disease and intestinal permeability[[51](#_ENREF_51),[52](#_ENREF_52)].

Similarly, in non-alcoholic fatty liver disease (NAFLD), PAMPs reach the liver *via* the portal venous circulation and induce tumor-necrosis-factor-dependent inflammatory pathways in the liver[[15](#_ENREF_15),[53](#_ENREF_53)]. Intestinal dysbiosis was found to be more aggravated in NAFLD patients with advanced liver fibrosis, and metagenomic analysis achieved high accuracy in detecting advanced fibrosis in patients with NAFLD[[54](#_ENREF_54)]. In another study, changes in microbiota composition were linked to the development of hepatic encephalopathy[[55](#_ENREF_55)].

The significance of gut-liver crosstalk is further emphasized by studies that demonstrate a connection between HCC development and tumor progression to chronic hepatic inflammation caused by BT[[56](#_ENREF_56)]. For example, TLR activation by LPS promotes not only fibrosis but also hepatocarcinogenesis[[57](#_ENREF_57),[58](#_ENREF_58)], while blockade of the TLR4 signaling cascade reduces HCC formation[[59](#_ENREF_59),[60](#_ENREF_60)]. Orci *et al*[[61](#_ENREF_61)] recently investigated the role of TLR4-mediated pathways in HCC recurrence in mice that underwent temporary clamping of portal vessels to induce ischemic liver injury. The resulting obstruction of splanchnic blood flow resulted in increased BT and promotion of HCC recurrence *via* TLR4 signaling pathways. Importantly, ischemic preconditioning, intestinal decontamination and interference with TLR4 signaling impeded tumor recurrence. In summary, these observations point towards the connection between pathological changes in the intestines and ACLD.

**FUNCTIONALITY OF THE INTESTINAL BARRIER AND THE ROLE OF BILE ACID SIGNALING**

***Intestinal barrier: Physiological and pathophysiological aspects***

The intestinal barrier is composed of multiple components in different layers of the intestinal wall and functions as a highly specialized obstacle for translocation of gut-derived pathogens while allowing passage of nutrients, water, electrolytes, and hormones. Whereas the hydrophobic nature of cell membranes of epithelial cells prevents direct passage of most hydrophilic molecules, restriction of paracellular passage and mechanical integrity of the epithelium is ensured by - from apical to basal-tight junctions (TJ) [zonula occludens (ZO)], adherens junctions (AJ) (zonula adherens), and desmosomes (macula adherens)[[62](#_ENREF_62)]. The main purpose of TJ lies in preventing paracellular translocation, while AJ and desmosomes primarily provide intercellular connection, thus causing proximity between epithelial cells that is vital for TJ formation[[62](#_ENREF_62)]. In total, more than 50 proteins are involved in TJ formation-these proteins are usually subdivided into groups such as claudins, ZO proteins, and occludin.

Although claudin family members have similar properties, variation within certain regions cause differences in TJ charge selectivity and thus size and permeability of paracellular pores[[63-66](#_ENREF_63)]. Furthermore, the interaction of TJ proteins is highly dynamic and the majority of proteins do not remain bound in a steady-state fashion and are rather subjected to constant exchange[[67](#_ENREF_67)]. ZO-1 seems to be necessary for the binding interaction between occludin and the cytoskeleton at the TJ site[[68](#_ENREF_68)]. Moreover, the close interaction between TJ and AJ proteins is further supported by the finding that trafficking of ZO-1 from the cytosol to the cell membrane depends on catenins, *i.e.* essential components of AJ[[69](#_ENREF_69)]. In turn, cell adhesion by E-cadherin (*i.e.* an AJ component) is influenced by interaction of alpha-catenin with ZO-1[[70](#_ENREF_70)].

The intestinal epithelium is additionally protected by a mucous layer that provides a physical barrier between bacteria and epithelial cells. The mucous layer mainly consists of mucins (glycoproteins) produced by goblet cells[[71](#_ENREF_71),[72](#_ENREF_72)]. Additional host defense and protection of the epithelium is provided *via* secretion of antimicrobial peptides by Paneth cells[[73](#_ENREF_73)].

Importantly, bacteria that are entering the bloodstream are not only required to migrate across the epithelial barrier but also the vascular barrier that also contains TJ and AJ. The bacterium *Salmonella typhimurium*, for example, can penetrate the vascular barrier *via* interference with Wnt/β-catenin signaling that regulates E-cadherin/β-catenin, and thus, AJ functionality[[74](#_ENREF_74),[75](#_ENREF_75)]. Importantly, hepatitis B virus infection also interferes with Wnt/β-catenin signaling[[76](#_ENREF_76)].

Considering the knowledge on the complex systems regulating intestinal permeability, it is imperative for translational research to explore alterations of mucosal barrier function in ACLD (Figure 2). In this regard, it was found that alcohol exposure decreases expression levels of TJ proteins[[77](#_ENREF_77),[78](#_ENREF_78)]. Certain detrimental effects of alcohol on the intestinal barrier can be attributed to its metabolite acetaldehyde, which dysregulates protein phosphatases and kinases that ensure TJ and AJ integrity between intestinal epithelial cells[[79-83](#_ENREF_79)]. Additionally, decreased production of antimicrobial peptides by Paneth cells was found to be associated with BT in cirrhotic animals[[84](#_ENREF_84)]. The finding that the inflammation marker IL-6 increases TJ permeability for small molecules *via* upregulation of the claudin-2 gene does not give a rationale for BT caused by IL-6 *per se*, but may rather suggest that a pro-inflammatory state during liver disease also impacts on gut permeability[[85](#_ENREF_85)]. In contrast, the inflammatory cytokines interferon-γ and TNF-α have been shown to increase gut permeability by downregulation of TJ proteins[[86-89](#_ENREF_86)].

Some pharmacological agents that are currently tested for the treatment of liver disease were shown to effect the expression profile of certain TJ proteins in the gut epithelium[[90](#_ENREF_90),[91](#_ENREF_91)], which gives a clinical and therapeutic perspective that will be summarized in another chapter of this review.

***Intestinal permeability is linked to PHT***

In the setting of PHT, the elevated plasma volume and increased intravascular pressure in splanchnic vessels influence not only vascular but also intestinal permeability[[92](#_ENREF_92)]. Again, a potential pathophysiological mechanism that links PHT to BT lies in the congestion of the blood flow in the portal vein back to intestinal mucosal microcirculation. In this context, chronic exposure to elevated portal pressure impairs microcirculation, promotes neoangiogenesis, and increases permeability in the splanchnic vasculature[[12](#_ENREF_12),[93](#_ENREF_93)]. Ultimately, these vascular changes also affect intestinal barrier function.

An experimental study comparing two rat models of PHT, partial portal vein ligation (PPVL) and common bile duct ligation (BDL), demonstrated that angiogenesis in the splanchnic vessels is increased in both models[[94](#_ENREF_94)]. Similarly, vascular endothelial growth factor and endothelial nitric oxide synthase were elevated in PPVL and BDL rats. Conversely, microvascular leakage of macromolecules was only observed in the BDL model, indicating that liver damage and/or cholestasis further aggravate the disrupted homeostasis of neovascularization and vessel integrity[[94](#_ENREF_94)].

In an exploratory human study, patients with PHT had increased dilatation of intercellular spaces in the jejunum as compared to healthy controls[[95](#_ENREF_95)], as well as increased spaces between duodenal enterocytes and shortening and decreased density of microvilli[[96](#_ENREF_96)]. Furthermore, patients with PHT had increased vessel diameters within the jejunal and duodenal mucosa, edema within the subepithelial lamina propria, as well as a decline of villous/crypt ratio[[97](#_ENREF_97)]. However, these and other studies in humans are often limited by small sample sizes and insufficient patient characterization of by means of etiology, HVPG, and liver disease stage. Still, there are several studies in patients with portal hypertensive gastropathy that indicate increased gastrointestinal permeability[[93](#_ENREF_93),[98-100](#_ENREF_98)].

The finding that soluble CD163 (sCD163) correlates with the HVPG has provided a biomarker-derived link between the immune system and PHT[[101](#_ENREF_101)]. For example, together with serum fibrosis markers, sCD163 can predict CSPH with very high accuracy[[102](#_ENREF_102)]. The protein CD163 functions as a hemoglobin-haptoglobin scavenger receptor and represents activation of Kupffer cells and macrophages as it is released into the circulatory blood system (*i.e.* as sCD163) upon TLR activation[[103](#_ENREF_103),[104](#_ENREF_104)]. sCD163 levels were found to be significantly higher in the hepatic vein as compared to the portal vein, supporting that liver-resident immune cells are indeed a significant source of elevated sCD163 serum concentrations[[105](#_ENREF_105)].

Interestingly, patients receiving transjugular intrahepatic portosystemic shunting (TIPS) to reduce portal pressure had a post-interventional decline of LPS-binding protein (LBP), whereas sCD163 concentrations remained unchanged[[105](#_ENREF_105)]. Similarly, markers of inflammation decline after TIPS implantation but remain independent predictors of death, raising the question whether systemic inflammation and the role of BT remain important factors in the course of disease in some patients, even when the severity of PHT is successfully reduced by established treatment strategies[[106](#_ENREF_106),[107](#_ENREF_107)]. In addition, this observation reveals the uncertainty which factors contributing to progression or regression of disease remain or become relevant after etiological treatment of liver disease. Recent findings in animal models of cirrhosis indicate that extrahepatic vascular changes (such as angiogenesis, shunting and increased splanchnic blood flow) persist and may represent an important cause of impaired regression of PHT[[108](#_ENREF_108),[109](#_ENREF_109)]. Based on the findings of this study, it may also be speculated that structural changes disturbing the gut barrier function persist, despite a substantial reduction in intrahepatic resistance/portal pressure by etiological treatments or TIPS. In the study of Holland-Fischer *et al*[[105](#_ENREF_105)], however, LBP levels of patients almost normalized after receiving TIPS.

***Bile acids: Communicators between liver and gut in health and disease***

The microbiome composition is considered to impact on the intestinal barrier integrity during liver disease and unfavorable shifts towards pathogenic bacteria have been found in both experimental and clinical studies, as extensively reviewed by others[[13](#_ENREF_13),[15](#_ENREF_15),[54](#_ENREF_54)].

In an animal model of primary sclerosing cholangitis (PSC), *Klebsiella pneumoniae* was recently shown to induce pore formation in the epithelial layer, as well as priming of T-cells in the liver that lead to aggravation of hepatobiliary damage. In this study, the synergistic effect of multiple pathobionts was also suggested, which seems to be the most likely scenario in human disease[[110](#_ENREF_110)]. In turn, the microbiota composition depends on the level and hydrophilicity of intestinal bile acids, that likely represent another important link between liver disease and gut barrier integrity[[111](#_ENREF_111)]. Multidrug resistance protein 2 knockout mice (*i.e.* an animal model for PSC) were recently found to have significant changes in microbiota and serum BA composition. Interestingly, microbiota transfer to wild type mice led to liver injury which was associated with activation of the NLRP3 inflammasome in both liver and intestines[[112](#_ENREF_112)].

BAs both exert direct effects on bacterial dysbiosis and adhesion *via* interaction with microbial membrane lipids and proteins that cause changes in membrane integrity, leakage, and cell death[[113-119](#_ENREF_113)]. BAs undergo enterohepatic circulation, which is characterized by secretion, reabsorption and recycling of primary and secondary BAs[[15](#_ENREF_15)]. Primary BAs are produced from cholesterol in hepatocytes and are secreted into the bile duct. Most BAs (about 95%) are reabsorbed in the terminal ileum *via* active transport mechanisms, transported back to the liver in the portal venous system and recycled by hepatocytes[[120](#_ENREF_120)]. Conversely, a small percentage of BAs is metabolized by intestinal bacteria. These so-called secondary BAs are passively absorbed into the systemic circulation[[15](#_ENREF_15),[121](#_ENREF_121)].

In physiological conditions (“neutral” pathway), cholesterol 7α-hydroxylase (CYP7A1) is the most important rate-limiting enzyme for primary BA synthesis. Alternative pathways (“acidic” pathways) to synthesize BA, including mitochondrial sterol 27 hydroxylase (CYP27A1) and sterol 12α-hydroxylase (CYP8B1), are only responsible for a minority of BA synthesis in healthy humans. However, this equilibrium shifts towards the acidic pathways in patients with liver disease[[122](#_ENREF_122),[123](#_ENREF_123)]. Importantly, these bile acids have slightly different chemical properties. The resulting differences of bile acid composition in liver disease were linked to intestinal barrier dysfunction and permeability[[122](#_ENREF_122),[124](#_ENREF_124),[125](#_ENREF_125)]. Additionally, LPS was found to significantly suppress the expression of CYP7A1 in the liver. These findings suggest that dysregulated BA homeostasis participates in a vicious circle towards an impaired gut barrier function[[126](#_ENREF_126)].

***Farnesoid X receptor activation affects intestinal barrier integrity***

BAs also exert direct effects on gut barrier integrity *via* activation of the nuclear bile acid receptor [farnesoid X receptor (FXR)] in the intestinal epithelium[[111](#_ENREF_111),[127](#_ENREF_127)]. FXR belongs to the group of non-steroidal nuclear receptors and acts as a transcription factor through binding to hormone response elements upon activation. Similar to other receptors in this family, DNA binding requires heterodimer formation with retinoic acid receptor α (RXRα)[[128](#_ENREF_128)]. FXR is expressed both in liver and gut, with highest expression levels located in the ileum[[129](#_ENREF_129)]. More precisely, FXR is located in the epithelium, while there is little or no expression in layers beneath, such as lamina propria and tunica muscularis[[127](#_ENREF_127)]. Decreased intestinal BA availability in cholestatic animal models is associated with increased BT and endotoxemia. Conversely, concomitant oral administration of BAs has beneficial effects on BT[[130](#_ENREF_130),[131](#_ENREF_131)]. Importantly, FXR activation leads to upregulation of genes associated with intestinal protection, gut barrier integrity, and amelioration of dysbiosis[[127](#_ENREF_127)]. Administration of pharmacological FXR agonists was found to ameliorate the microbiota profile, increase antimicrobial peptides and expression of tight junction proteins, and finally, reduce BT[[91](#_ENREF_91)].

In mice, FXR activation in enterocytes located in the ileum upregulates the expression of fibroblast growth factor (FGF) 15, the murine analogue of human FGF19, *via* binding to response elements for the FGF15/19 gene[[132](#_ENREF_132),[133](#_ENREF_133)]. Importantly, binding to the FGF19 gene response element relies on heterodimer formation with RXRα[[134](#_ENREF_134)]. FGF15/19 is subsequently secreted into the portal venous blood system and functions as a hormone of gut-liver signaling[[132](#_ENREF_132),[133](#_ENREF_133)]. FGF19 binds to FGF receptor 4 located on hepatocytes and reduces BA synthesis by suppressing the expression of CYP7A1[[134](#_ENREF_134)].

Interestingly, short-term suppression of CYP7A1 is rather dependent on intestinal than hepatic FXR activation[[135](#_ENREF_135)]. Of note, this pathway seems to be independent from FXR-induced expression of small heterodimer partner 1 that also suppresses CYP7A1 *via* liver receptor homolog 1[[136](#_ENREF_136)], suggesting two major mechanisms of FXR-dependent BA feedback that are independent from each other[[134](#_ENREF_134)]. Furthermore, FGF19 is postprandially upregulated and influences FXR-dependent pathways involved in gluconeogenesis, protein synthesis, insulin sensitivity, and lipid metabolism[[133](#_ENREF_133),[134](#_ENREF_134),[137](#_ENREF_137)]. Recent findings indicate that FGF19-induced phosphorylation of FXR is critical for heterodimerization with RXRα, migration to the nucleus, and DNA binding– a mechanism that is impaired *e.g.* in patients with primary biliary cholangitis (PBC)[[138](#_ENREF_138)]. This is in accordance with the finding that FGF19 is upregulated in PBC patients and correlates with disease severity[[139](#_ENREF_139)]. Along with the effects of FXR activation on the expression of proteins involved in the formation of the intestinal barrier, these findings indicate clinical relevance of FXR-FGF19 feedback mechanisms.

***Addressing the “chicken vs egg” dilemma***

The data on BT and its impact on hepatic and systemic inflammation *vs* splanchnic neoangiogenesis and vasodilation caused by PHT reveals the “chicken *vs* egg” dilemma concerning the gut-liver axis hypothesis: It currently remains elusive if microbiota changes and BT are primarily caused by PHT, or if the presence of PHT and its severity are rather a result of BT. It seems likely that there exists bidirectional influence, however, clinical studies usually fail to separate whether BT is the main cause for disease progression or is in turn the result of liver injury and PHT. However, studies on genetic variants that facilitate BT might provide important insights in this conundrum. Impact of genetic polymorphisms that impact on signaling pathways involved in intestinal barrier or BT do not leave us with the question “cause or consequence of disease progression” since this particular genetic condition is inherently present in affected patients.

For example, it was found that patients with a genetic variant of the nuclear dot protein 52 kDa (NDP52; regulates TLR signaling pathways) gene[[140](#_ENREF_140)] or TLR2 variants had an increased risk for spontaneous bacterial peritonitis (SBP)[[141](#_ENREF_141)]. Similarly, Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) variants were associated with an increased risk of developing SBP and mortality[[142](#_ENREF_142),[143](#_ENREF_143)]. NOD2 recognizes intracellular peptidoglycan fragments of bacteria and induces formation of autophagosomes as well as host-defense mechanisms such as cytokines and antimicrobial peptides[[144](#_ENREF_144)]. Patients carrying NOD2 variants had increased markers of intestinal permeability and inflammation[[93](#_ENREF_93),[145](#_ENREF_145)]. Interestingly, Reichert *et al*[[146](#_ENREF_146)] recently showed that NOD2 variants as well as CSPH are independently associated with bacterial infections in compensated cirrhosis. In contrast, only CSPH- and not NOD2 variants- remained an independent risk factor for infection in decompensated patients.

FXR polymorphisms in humans have been shown to either promote or protect against hepatic decompensation. For example, the *rs56163822* G/T polymorphism was significantly more prevalent in patients developing SBP[[147](#_ENREF_147)]. This specific polymorphism is associated with decreased translation of FXR and reduced transcriptional activity of target genes[[148](#_ENREF_148),[149](#_ENREF_149)]. In contrast, patients with the FXR-SNP rs35724 minor allele (*i.e.* FXR gain of function mutation) were less likely to develop ascites or liver-related death[[150](#_ENREF_150)].

Interestingly, Sorribas *et al*[[151](#_ENREF_151)] recently found that the gut-vascular and mucosal epithelial barriers were profoundly impaired in cirrhotic mice (induced by BDL or carbontetrachloride administration, CCl4) while this effect was not present, or at least significantly less pronounced, in portal-hypertensive mice without cirrhosis (PPVL). Importantly, it was observed that these barriers were regulated by FXR-dependent mechanisms (Figure 1), and BT was reduced upon treatment with FXR agonists[[151](#_ENREF_151)].

These experimental data are highly relevant for the “chicken *vs* egg” debate because they suggest that PHT itself has only a minor impact on barrier integrity, while it also explicitly considers that the muco-epithelial and gut-vascular barrier are different entities. Along with observations from genetic studies that suggest that BT and inflammation do not only result from decompensation but rather are drivers of (further) hepatic decompensation, efforts towards elucidating this conundrum have the potential to identify therapeutic approaches in patients with cirrhosis and PHT.

**THERAPEUTIC STRATEGIES TARGETING THE GUT-LIVER AXIS**

Importantly, the identification and targeting of potentially reversible causes of liver injury and their elimination will always remain the main management priority in patients with chronic liver disease. In ALD, the most common cause of cirrhosis in Europe[[4](#_ENREF_4)], alcohol abstinence improves PHT[[152](#_ENREF_152)] and the prognosis of patients in both early and advanced stages of cirrhosis[[153](#_ENREF_153),[154](#_ENREF_154)]. Similarly, weight loss in NASH patients was linked to fibrosis regression and NASH resolution[[155](#_ENREF_155)], and elimination of hepatitis C virus by direct antiviral agents results in reduction of PHT and HCC risk[[156-159](#_ENREF_156)].

As depicted above, PHT impacts on the course of cirrhosis by promoting hepatic decompensation and ACLF, hemodynamic dysregulation as well as intestinal permeability and BT. In turn, PHT is aggravated by hyperdynamic circulation and also proinflammatory and profibrotic stimuli caused by BT. This reciprocal influence contributes to further aggravation of the disease and also promotes carcinogenesis, which has been shown in different etiologies of liver disease[[14](#_ENREF_14),[17](#_ENREF_17),[41](#_ENREF_41),[160](#_ENREF_160),[161](#_ENREF_161)]. Thus, evidence-based therapeutic options to positively influence or ideally break the vicious circle of a dysregulated gut-liver axis in cirrhosis are urgently needed. Consequently, therapeutic approaches that target PHT, intestinal permeability, and the microbiome composition may be all viable future therapeutic options for improving prognosis and risk of further disease aggravation. Importantly, some of these therapeutic approaches are currently being investigated in clinical trials in humans[[160](#_ENREF_160)].

***Reduction of PHT: Non-selective beta-blockers***

According to current treatment guidelines, NSBB are used for pharmacological reduction of PHT in patients with cirrhosis[[1](#_ENREF_1),[162](#_ENREF_162)]. The treatment rationale of NSBB is primarily based on beneficial effects towards prevention of decompensation such as variceal bleeding[[21](#_ENREF_21),[163](#_ENREF_163),[164](#_ENREF_164)]. Additionally, cirrhotic patients under NSBB treatment presenting with ACLF were found to have lower grades of liver failure as well as better chances of short-term (but not long-term) survival as compared to patients not receiving NSBB treatment, which was accompanied by lower white blood cell counts[[165](#_ENREF_165)]. Of note, in this study patients were not randomized to receive NSBB treatment and the decision process on treatment initiation or discontinuation was not assessed[[165](#_ENREF_165)]. Importantly, based on animal data indicating beneficial effects on BT[[166](#_ENREF_166)] it was found that markers of intestinal permeability and BT decreased upon NSBB treatment in patients with cirrhosis[[93](#_ENREF_93)]. This effect was also observed in patients without significant reduction of HVPG by NSBB treatment (“non-responders”), suggesting that even hemodynamic non-responders may benefit from continuation of NSBB treatment[[93](#_ENREF_93)].

***Targeting the microbiome and BT: Antibiotics, probiotics and the role of proton pump inhibitors***

Current guidelines recommend continuous prophylaxis with antibiotics for patients with cirrhosis either at particularly high risk of or after SBP[[7](#_ENREF_7)]. Primary prophylaxis with norfloxacin significantly reduces the incidence of infections, however, it is not entirely clear by now which patients with ascites actually have survival benefits upon primary prophylaxis[[167](#_ENREF_167),[168](#_ENREF_168)]. Patients with genetic variants that increase susceptibility for developing infections may represent an interesting target population for antibiotic prophylaxis. The currently ongoing INCA trial (EudraCT 2013-001626-26) will hopefully provide data on the efficacy of primary prophylaxis in patients with NOD2 risk variants[[169](#_ENREF_169)].

Survival benefits and decreased risk of AD and ACLF were found upon antibiotic treatment at the occurrence of variceal bleeding[[7](#_ENREF_7)]. Currently, fluoroquinolones (such as norfloxacin and ciprofloxacin) and third generation cephalosporins are recommended first line antibiotic regimens to be used in acute variceal bleeding[[7](#_ENREF_7)] in order to prevent infections.

Moreover, the portal pressure-lowing effect of norfloxacin has been investigated. A small randomized controlled trial (RCT) with a cross-over design assessed the effect of 4-wk therapy with norfloxacin and did not result in significant reduction of portal pressure. However, sample size was limited and considerable changes in HVPG during placebo treatment were observed[[170](#_ENREF_170)]. Another RCT investigating the effect of 4-wk norfloxacin therapy on hemodynamics found that patients with cirrhosis had a reduction of serum LPS and higher mean arterial pressure, while there was a trend towards a reduction of cardiac output and HVPG. Although the trial was limited by a small sample size, these observations might indicate that inducing changes in microbiota composition influences BT and positively influences hyperdynamic circulation in patients with cirrhosis[[171](#_ENREF_171)].

Moreover, non-absorbable antibiotics such as rifaximin are currently used for the treatment of hepatic encephalopathy. However, there is conflicting data on the efficacy towards BT, systemic inflammation and hemodynamics: Some studies present significant beneficial effects on systemic inflammation and hemodynamics[[172](#_ENREF_172),[173](#_ENREF_173)], while another RCT found no or only small benefits by rifaximin treatment[[174](#_ENREF_174),[175](#_ENREF_175)]. The results of currently ongoing trials on rifaximin will hopefully provide further insight into treatment efficacy and the role of treatment-induced microbiome changes in cirrhosis[[176](#_ENREF_176)].

Probiotics, *i.e.* bacteria that modify microbiome composition and mucosal integrity by suppression of pathogenic bacteria, are currently studied extensively. However, there is conflicting data on the efficacy of probiotics, which has been extensively reviewed by Wiest *et al*[[160](#_ENREF_160)]. The authors summarize that positive effects of probiotics are greatly dependent on host genetic properties, individual diet and microbiome composition.

Lastly, awareness towards prudent use of proton pump inhibitors (PPI) in patients with cirrhosis should be encouraged: PPI intake has been repeatedly found to be associated with increased risk of developing hepatic encephalopathy and infections, such as SBP[[177-179](#_ENREF_177)]. Interestingly, PPIs induce both significant change of the microbiome composition as well as bacterial metabolism in patients with compensated cirrhosis[[180](#_ENREF_180)]. Although the data may not prove causality between PPI intake and BT, cautious prescription of PPIs in patients with cirrhosis is warranted.

***Mediating gut-liver-crosstalk: FXR-directed therapies***

As depicted above, BA-associated signaling in the gut and the liver plays a major role in the gut-liver axis. Many effects are mediated *via* binding of BA to the nuclear receptor FXR[[181](#_ENREF_181)]. Therefore, several pharmacological compounds targeting FXR have emerged in the last years (Table 1).

Treatment with the FXR agonist obeticholic acid (OCA) upregulates expression of tight junction proteins (*e.g.,* ZO-1, occludin and claudin-1/2), antimicrobial molecules (*e.g.,* angiogenin-1 and alpha-5-defensin) and reduces BT and intestinal inflammation in cirrhotic rats[[90](#_ENREF_90),[91](#_ENREF_91),[127](#_ENREF_127)]. Similarly, activation of hepatic inflammatory pathways and fibrogenesis were reduced in animals upon OCA treatment[[182](#_ENREF_182)]. OCA has primarily been tested in clinical trials including patients with PBC and NASH. The FLINT RCT in non-cirrhotic NASH patients indicated that OCA improves histological features of the disease, however, pruritus seems to be an inconvenient side effect that was reported by approximately one fifth of patients[[183](#_ENREF_183)]. Furthermore, unfavorable changes in the lipid profile (increase of total and LDL cholesterol) were observed upon OCA treatment[[183](#_ENREF_183)]. In two RCTs in PBC patients, OCA improved serum levels of transaminases and bilirubin, however, side effects like pruritus were also more frequent in the treatment groups as compared to placebo[[184](#_ENREF_184),[185](#_ENREF_185)]. Another safety issue towards treatment with FXR-activators was raised by an animal study indicating that overexpression of FGF19 is associated with HCC[[186](#_ENREF_186)]. Further study results of trials investigating OCA treatment in NASH (REGENERATE; NCT02548351), ALD (TREAT; NCT02039219), and PSC (AESOP; NCT02177136) are pending. Recent presentation of an interim analysis of the REGENERATE trial revealed dose-dependent positive effects of OCA on liver fibrosis, steatohepatitis and serum parameters associated with liver damage[[187](#_ENREF_187)]. Importantly, short-term treatment with the steroidal FXR agonist OCA in cirrhotic patients with PHT (PESTO trial) has shown promising results in regard to a significant reduction of HVPG[[188](#_ENREF_188)].

Newly emerging, non-steroidal FXR-agonists might be associated with an improved side effect profile as compared to OCA and showed promising results in metabolic liver disease[[160](#_ENREF_160)]. Treatment with the non-absorbable FXR agonist fexaramine that only affects intestinal FXR has shown positive results towards steatosis and glucose homeostasis in animals and may represent an elegant solution for intestinal FXR targeting with a favorable side effect profile[[189](#_ENREF_189)]. Fexaramine was also associated with improvement of the intestinal barrier, lipid metabolism and alcohol-induced liver injury[[190](#_ENREF_190)]. Experimental data in the field of inflammatory bowel disease shows a decrease of proinflammatory cytokines by intestinal immune cells that are associated with increased gut permeability upon FXR activation[[191](#_ENREF_191)]. In cirrhotic animals, a non-steroidal FXR-agonist reduced PHT, BT and vascular remodeling[[192](#_ENREF_192)]. The non-tumorigenic FGF19 analogue NGM282 was associated with reduced fibrosis biomarkers in a phase II trial in humans with PSC, indicating an amelioration of fibrosis which may also be accompanied by an amelioration of PHT. However, histological and hemodynamic data were not obtained within this study[[193](#_ENREF_193)].

Taken together, therapeutics that target FXR are likely to have beneficial effects on the gut-liver axis in cirrhosis, provided that potential side effects will be successfully minimized by recent efforts to find even more suitable compounds.

**CONCLUSION**

In ACLD, PHT results from increased intrahepatic resistance and leads to splanchnic vasodilation and neovascularization in the intestines. Gut dysbiosis, increased intestinal permeability, translocation of bacteria and PAMPs can further promote liver disease progression, often mediated *via* immune system activation and a subsequent induction of a proinflammatory state. The close relationship between gut and liver and their bidirectional interaction during liver disease has been termed gut-liver axis. Treatment strategies targeting the gut-liver axis *via* amelioration of PHT, microbiota composition, and intestinal barrier integrity are supposed to exert beneficial effects. However, further studies in humans will be needed to assess efficacy and safety of different FXR agonists and other gut-liver axis-oriented therapies in different clinical settings. In general, further insight into the pathophysiology involved in the “chicken and the egg” dilemma may reveal important novel targets that inhibit liver disease progression or promote disease regression after etiological treatment. While this review aims to comprehensively summarize the current state of knowledge obtained by experimental and clinical studies, it is designed as a narrative review. Thus, the possibility of selection bias and underreporting of negative studies represents a potential limitation of this review.

**ACKNOWLEDGEMENTS**

Figures were created by including images from the Mind the Graph platform, available at www.mindthegraph.com

**REFERENCES**

1 **de Franchis R**, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

2 **GBD 2013 DALYs and HALE Collaborators**, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Ackerman IN, Ademi Z, Adou AK, Adsuar JC, Afshin A, Agardh EE, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Alla F, Allebeck P, Almazroa MA, Alsharif U, Alvarez E, Alvis-Guzman N, Amare AT, Ameh EA, Amini H, Ammar W, Anderson HR, Anderson BO, Antonio CA, Anwari P, Arnlöv J, Arsic Arsenijevic VS, Artaman A, Asghar RJ, Assadi R, Atkins LS, Avila MA, Awuah B, Bachman VF, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Basu A, Basu S, Basulaiman MO, Beardsley J, Bedi N, Beghi E, Bekele T, Bell ML, Benjet C, Bennett DA, Bensenor IM, Benzian H, Bernabé E, Bertozzi-Villa A, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Bienhoff K, Bikbov B, Biryukov S, Blore JD, Blosser CD, Blyth FM, Bohensky MA, Bolliger IW, Bora Başara B, Bornstein NM, Bose D, Boufous S, Bourne RR, Boyers LN, Brainin M, Brayne CE, Brazinova A, Breitborde NJ, Brenner H, Briggs AD, Brooks PM, Brown JC, Brugha TS, Buchbinder R, Buckle GC, Budke CM, Bulchis A, Bulloch AG, Campos-Nonato IR, Carabin H, Carapetis JR, Cárdenas R, Carpenter DO, Caso V, Castañeda-Orjuela CA, Castro RE, Catalá-López F, Cavalleri F, Çavlin A, Chadha VK, Chang JC, Charlson FJ, Chen H, Chen W, Chiang PP, Chimed-Ochir O, Chowdhury R, Christensen H, Christophi CA, Cirillo M, Coates MM, Coffeng LE, Coggeshall MS, Colistro V, Colquhoun SM, Cooke GS, Cooper C, Cooper LT, Coppola LM, Cortinovis M, Criqui MH, Crump JA, Cuevas-Nasu L, Danawi H, Dandona L, Dandona R, Dansereau E, Dargan PI, Davey G, Davis A, Davitoiu DV, Dayama A, De Leo D, Degenhardt L, Del Pozo-Cruz B, Dellavalle RP, Deribe K, Derrett S, Des Jarlais DC, Dessalegn M, Dharmaratne SD, Dherani MK, Diaz-Torné C, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Duber HC, Ebel BE, Edmond KM, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Estep K, Faraon EJ, Farzadfar F, Fay DF, Feigin VL, Felson DT, Fereshtehnejad SM, Fernandes JG, Ferrari AJ, Fitzmaurice C, Flaxman AD, Fleming TD, Foigt N, Forouzanfar MH, Fowkes FG, Paleo UF, Franklin RC, Fürst T, Gabbe B, Gaffikin L, Gankpé FG, Geleijnse JM, Gessner BD, Gething P, Gibney KB, Giroud M, Giussani G, Gomez Dantes H, Gona P, González-Medina D, Gosselin RA, Gotay CC, Goto A, Gouda HN, Graetz N, Gugnani HC, Gupta R, Gupta R, Gutiérrez RA, Haagsma J, Hafezi-Nejad N, Hagan H, Halasa YA, Hamadeh RR, Hamavid H, Hammami M, Hancock J, Hankey GJ, Hansen GM, Hao Y, Harb HL, Haro JM, Havmoeller R, Hay SI, Hay RJ, Heredia-Pi IB, Heuton KR, Heydarpour P, Higashi H, Hijar M, Hoek HW, Hoffman HJ, Hosgood HD, Hossain M, Hotez PJ, Hoy DG, Hsairi M, Hu G, Huang C, Huang JJ, Husseini A, Huynh C, Iannarone ML, Iburg KM, Innos K, Inoue M, Islami F, Jacobsen KH, Jarvis DL, Jassal SK, Jee SH, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jonas JB, Juel K, Kan H, Karch A, Karema CK, Karimkhani C, Karthikeyan G, Kassebaum NJ, Kaul A, Kawakami N, Kazanjan K, Kemp AH, Kengne AP, Keren A, Khader YS, Khalifa SE, Khan EA, Khan G, Khang YH, Kieling C, Kim D, Kim S, Kim Y, Kinfu Y, Kinge JM, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kosen S, Krishnaswami S, Kuate Defo B, Kucuk Bicer B, Kuipers EJ, Kulkarni C, Kulkarni VS, Kumar GA, Kyu HH, Lai T, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larsson A, Lawrynowicz AE, Leasher JL, Leigh J, Leung R, Levitz CE, Li B, Li Y, Li Y, Lim SS, Lind M, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Lofgren KT, Logroscino G, Looker KJ, Lortet-Tieulent J, Lotufo PA, Lozano R, Lucas RM, Lunevicius R, Lyons RA, Ma S, Macintyre MF, Mackay MT, Majdan M, Malekzadeh R, Marcenes W, Margolis DJ, Margono C, Marzan MB, Masci JR, Mashal MT, Matzopoulos R, Mayosi BM, Mazorodze TT, Mcgill NW, Mcgrath JJ, Mckee M, Mclain A, Meaney PA, Medina C, Mehndiratta MM, Mekonnen W, Melaku YA, Meltzer M, Memish ZA, Mensah GA, Meretoja A, Mhimbira FA, Micha R, Miller TR, Mills EJ, Mitchell PB, Mock CN, Mohamed Ibrahim N, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Montañez Hernandez JC, Montico M, Montine TJ, Mooney MD, Moore AR, Moradi-Lakeh M, Moran AE, Mori R, Moschandreas J, Moturi WN, Moyer ML, Mozaffarian D, Msemburi WT, Mueller UO, Mukaigawara M, Mullany EC, Murdoch ME, Murray J, Murthy KS, Naghavi M, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Narayan KM, Nejjari C, Neupane SP, Newton CR, Ng M, Ngalesoni FN, Nguyen G, Nisar MI, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Oh IH, Ohkubo T, Ohno SL, Olusanya BO, Opio JN, Ortblad K, Ortiz A, Pain AW, Pandian JD, Panelo CI, Papachristou C, Park EK, Park JH, Patten SB, Patton GC, Paul VK, Pavlin BI, Pearce N, Pereira DM, Perez-Padilla R, Perez-Ruiz F, Perico N, Pervaiz A, Pesudovs K, Peterson CB, Petzold M, Phillips MR, Phillips BK, Phillips DE, Piel FB, Plass D, Poenaru D, Polinder S, Pope D, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Prasad NM, Pullan RL, Qato DM, Quistberg DA, Rafay A, Rahimi K, Rahman SU, Raju M, Rana SM, Razavi H, Reddy KS, Refaat A, Remuzzi G, Resnikoff S, Ribeiro AL, Richardson L, Richardus JH, Roberts DA, Rojas-Rueda D, Ronfani L, Roth GA, Rothenbacher D, Rothstein DH, Rowley JT, Roy N, Ruhago GM, Saeedi MY, Saha S, Sahraian MA, Sampson UK, Sanabria JR, Sandar L, Santos IS, Satpathy M, Sawhney M, Scarborough P, Schneider IJ, Schöttker B, Schumacher AE, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Serina PT, Servan-Mori EE, Shackelford KA, Shaheen A, Shahraz S, Shamah Levy T, Shangguan S, She J, Sheikhbahaei S, Shi P, Shibuya K, Shinohara Y, Shiri R, Shishani K, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Simard EP, Sindi S, Singh A, Singh JA, Singh L, Skirbekk V, Slepak EL, Sliwa K, Soneji S, Søreide K, Soshnikov S, Sposato LA, Sreeramareddy CT, Stanaway JD, Stathopoulou V, Stein DJ, Stein MB, Steiner C, Steiner TJ, Stevens A, Stewart A, Stovner LJ, Stroumpoulis K, Sunguya BF, Swaminathan S, Swaroop M, Sykes BL, Tabb KM, Takahashi K, Tandon N, Tanne D, Tanner M, Tavakkoli M, Taylor HR, Te Ao BJ, Tediosi F, Temesgen AM, Templin T, Ten Have M, Tenkorang EY, Terkawi AS, Thomson B, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tonelli M, Topouzis F, Toyoshima H, Traebert J, Tran BX, Trillini M, Truelsen T, Tsilimbaris M, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uzun SB, Van Brakel WH, Van De Vijver S, van Gool CH, Van Os J, Vasankari TJ, Venketasubramanian N, Violante FS, Vlassov VV, Vollset SE, Wagner GR, Wagner J, Waller SG, Wan X, Wang H, Wang J, Wang L, Warouw TS, Weichenthal S, Weiderpass E, Weintraub RG, Wenzhi W, Werdecker A, Westerman R, Whiteford HA, Wilkinson JD, Williams TN, Wolfe CD, Wolock TM, Woolf AD, Wulf S, Wurtz B, Xu G, Yan LL, Yano Y, Ye P, Yentür GK, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaki ME, Zhao Y, Zheng Y, Zonies D, Zou X, Salomon JA, Lopez AD, Vos T. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet* 2015; **386**: 2145-2191 [PMID: 26321261 DOI: 10.1016/S0140-6736(15)61340-X]

3 **Allen AM**, Kim WR. Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. *Semin Liver Dis* 2016; **36**: 123-126 [PMID: 27172353 DOI: 10.1055/s-0036-1583201]

4 **Pimpin L**, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. *J Hepatol* 2018; **69**: 718-735 [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011]

5 **Arroyo V**, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. *Nat Rev Dis Primers* 2016; **2**: 16041 [PMID: 27277335 DOI: 10.1038/nrdp.2016.41]

6 **Ginés P**, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; **7**: 122-128 [PMID: 3804191 DOI: 10.1002/hep.1840070124]

7 **European Association for the Study of the Liver**. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010; **53**: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]

8 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

9 **Blei AT**, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic Encephalopathy. *Am J Gastroenterol* 2001; **96**: 1968-1976 [PMID: 11467622 DOI: 10.1111/j.1572-0241.2001.03964.x]

10 **Garcia-Tsao G**, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. *N Engl J Med* 2010; **362**: 823-832 [PMID: 20200386 DOI: 10.1056/NEJMra0901512]

11 **Arvaniti V**, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. *Gastroenterology* 2010; **139**: 1246-1256 [PMID: 20558165 DOI: 10.1053/j.gastro.2010.06.019]

12 **Trebicka J**, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. *Visc Med* 2018; **34**: 270-275 [PMID: 30345284 DOI: 10.1159/000490262]

13 **Schnabl B**, Brenner DA. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology* 2014; **146**: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]

14 **Hartmann P**, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. *Alcohol Clin Exp Res* 2015; **39**: 763-775 [PMID: 25872593 DOI: 10.1111/acer.12704]

15 **Tripathi A**, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 397-411 [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z]

16 **Wiest R**, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005; **41**: 422-433 [PMID: 15723320 DOI: 10.1002/hep.20632]

17 **Bernardi M**, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. *J Hepatol* 2015; **63**: 1272-1284 [PMID: 26192220 DOI: 10.1016/j.jhep.2015.07.004]

18 **Schuppan D**, Afdhal NH. Liver cirrhosis. *Lancet* 2008; **371**: 838-851 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]

19 **Dooley JS**, Lok SA, Garcia-Tsao G, Pinzani M, Sherlock's diseases of the liver and biliary system. 12th ed. Wiley-Blackwell Pub, **2011**:103-120

20 **Tsochatzis EA**, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet* 2014; **383**: 1749-1761 [PMID: 24480518 DOI: 10.1016/S0140-6736(14)60121-5]

21 **Reiberger T**, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. *J Hepatol* 2017; **66**: 849-859 [PMID: 27864004 DOI: 10.1016/j.jhep.2016.11.001]

22 **Bosch J**, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. *J Hepatol* 2015; **62**: S121-S130 [PMID: 25920081 DOI: 10.1016/j.jhep.2015.01.003]

23 **Bosch J**, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 573-582 [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149]

24 **Ripoll C**, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. *J Hepatol* 2009; **50**: 923-928 [PMID: 19303163 DOI: 10.1016/j.jhep.2009.01.014]

25 **Villanueva C**, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, Bosch J. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. *Hepatology* 2016; **63**: 197-206 [PMID: 26422126 DOI: 10.1002/hep.28264]

26 **Turco L**, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, Colopi S, Simonini E, De Maria N, Banchelli F, Rossi R, Villa E, Schepis F. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. *J Hepatol* 2018; **68**: 949-958 [PMID: 29331339 DOI: 10.1016/j.jhep.2017.12.027]

27 **Pijls KE**, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. *Liver Int* 2013; **33**: 1457-1469 [PMID: 23879434 DOI: 10.1111/liv.12271]

28 **Groszmann RJ**. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. *Hepatology* 1994; **20**: 1359-1363 [PMID: 7927273 DOI: 10.1016/0270-9139(94)90780-3]

29 **Bolognesi M**, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. *World J Gastroenterol* 2014; **20**: 2555-2563 [PMID: 24627591 DOI: 10.3748/wjg.v20.i10.2555]

30 **Kawai T**, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 2010; **11**: 373-384 [PMID: 20404851 DOI: 10.1038/ni.1863]

31 **Janeway CA Jr**, Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002; **20**: 197-216 [PMID: 11861602 DOI: 10.1146/annurev.immunol.20.083001.084359]

32 **Akira S**, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006; **124**: 783-801 [PMID: 16497588 DOI: 10.1016/j.cell.2006.02.015]

33 **Sriskandan S**, Altmann DM. The immunology of sepsis. *J Pathol* 2008; **214**: 211-223 [PMID: 18161754 DOI: 10.1002/path.2274]

34 **Hotchkiss RS**, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; **348**: 138-150 [PMID: 12519925 DOI: 10.1056/NEJMra021333]

35 **Liu D**, Cao S, Zhou Y, Xiong Y. Recent advances in endotoxin tolerance. *J Cell Biochem* 2019; **120**: 56-70 [PMID: 30246452 DOI: 10.1002/jcb.27547]

36 **Racanelli V**, Rehermann B. The liver as an immunological organ. *Hepatology* 2006; **43**: S54-S62 [PMID: 16447271 DOI: 10.1002/hep.21060]

37 **Clària J**, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology* 2016; **64**: 1249-1264 [PMID: 27483394 DOI: 10.1002/hep.28740]

38 **Waidmann O**, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. *J Hepatol* 2013; **58**: 956-961 [PMID: 23333526 DOI: 10.1016/j.jhep.2013.01.005]

39 **Tilg H**, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. *N Engl J Med* 2000; **343**: 1467-1476 [PMID: 11078773 DOI: 10.1056/nejm200011163432007]

40 **Robinson MW**, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. *Cell Mol Immunol* 2016; **13**: 267-276 [PMID: 27063467 DOI: 10.1038/cmi.2016.3]

41 **Seki E**, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. *J Physiol* 2012; **590**: 447-458 [PMID: 22124143 DOI: 10.1113/jphysiol.2011.219691]

42 **Uesugi T**, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. *Hepatology* 2001; **34**: 101-108 [PMID: 11431739 DOI: 10.1053/jhep.2001.25350]

43 **Csak T**, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. *Hepatology* 2011; **54**: 133-144 [PMID: 21488066 DOI: 10.1002/hep.24341]

44 **Tacke F**. Targeting hepatic macrophages to treat liver diseases. *J Hepatol* 2017; **66**: 1300-1312 [PMID: 28267621 DOI: 10.1016/j.jhep.2017.02.026]

45 **Heymann F**, Tacke F. Immunology in the liver--from homeostasis to disease. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 88-110 [PMID: 26758786 DOI: 10.1038/nrgastro.2015.200]

46 **Szabo G**. Gut-liver axis in alcoholic liver disease. *Gastroenterology* 2015; **148**: 30-36 [PMID: 25447847 DOI: 10.1053/j.gastro.2014.10.042]

47 **Bala S**, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. *PLoS One* 2014; **9**: e96864 [PMID: 24828436 DOI: 10.1371/journal.pone.0096864]

48 **Bode C**, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. *J Hepatol* 1987; **4**: 8-14 [PMID: 3571935 DOI: 10.1016/S0168-8278(87)80003-X]

49 **Parlesak A**, Schäfer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. *J Hepatol* 2000; **32**: 742-747 [PMID: 10845660 DOI: 10.1016/S0168-8278(00)80242-1]

50 **Roh YS**, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. *Am J Physiol Gastrointest Liver Physiol* 2015; **309**: G30-G41 [PMID: 25930080 DOI: 10.1152/ajpgi.00031.2015]

51 **Lippai D**, Bala S, Catalano D, Kodys K, Szabo G. Micro-RNA-155 deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice. *Alcohol Clin Exp Res* 2014; **38**: 2217-2224 [PMID: 25156614 DOI: 10.1111/acer.12483]

52 **Yoseph BP**, Breed E, Overgaard CE, Ward CJ, Liang Z, Wagener ME, Lexcen DR, Lusczek ER, Beilman GJ, Burd EM, Farris AB, Guidot DM, Koval M, Ford ML, Coopersmith CM. Chronic alcohol ingestion increases mortality and organ injury in a murine model of septic peritonitis. *PLoS One* 2013; **8**: e62792 [PMID: 23717394 DOI: 10.1371/journal.pone.0062792]

53 **Henao-Mejia J**, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* 2012; **482**: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]

54 **Loomba R**, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab* 2017; **25**: 1054-1062.e5 [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001]

55 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019]

56 **Yu LX**, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 527-539 [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72]

57 **Dapito DH**, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. *Cancer Cell* 2012; **21**: 504-516 [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007]

58 **Seki E**, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 2007; **13**: 1324-1332 [PMID: 17952090 DOI: 10.1038/nm1663]

59 **Yu LX**, Yan HX, Liu Q, Yang W, Wu HP, Dong W, Tang L, Lin Y, He YQ, Zou SS, Wang C, Zhang HL, Cao GW, Wu MC, Wang HY. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. *Hepatology* 2010; **52**: 1322-1333 [PMID: 20803560 DOI: 10.1002/hep.23845]

60 **Weber SN**, Bohner A, Dapito DH, Schwabe RF, Lammert F. TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver. *PLoS One* 2016; **11**: e0158819 [PMID: 27391331 DOI: 10.1371/journal.pone.0158819]

61 **Orci LA**, Lacotte S, Delaune V, Slits F, Oldani G, Lazarevic V, Rossetti C, Rubbia-Brandt L, Morel P, Toso C. Effects of the gut-liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. *J Hepatol* 2018; **68**: 978-985 [PMID: 29331341 DOI: 10.1016/j.jhep.2017.12.025]

62 **Marchiando AM**, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. *Annu Rev Pathol* 2010; **5**: 119-144 [PMID: 20078218 DOI: 10.1146/annurev.pathol.4.110807.092135]

63 **Van Itallie CM**, Anderson JM. Architecture of tight junctions and principles of molecular composition. *Semin Cell Dev Biol* 2014; **36**: 157-165 [PMID: 25171873 DOI: 10.1016/j.semcdb.2014.08.011]

64 **Van Itallie CM**, Fanning AS, Anderson JM. Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. *Am J Physiol Renal Physiol* 2003; **285**: F1078-F1084 [PMID: 13129853 DOI: 10.1152/ajprenal.00116.2003]

65 **Yu AS**, Cheng MH, Angelow S, Günzel D, Kanzawa SA, Schneeberger EE, Fromm M, Coalson RD. Molecular basis for cation selectivity in claudin-2-based paracellular pores: identification of an electrostatic interaction site. *J Gen Physiol* 2009; **133**: 111-127 [PMID: 19114638 DOI: 10.1085/jgp.200810154]

66 **Van Itallie CM**, Holmes J, Bridges A, Gookin JL, Coccaro MR, Proctor W, Colegio OR, Anderson JM. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. *J Cell Sci* 2008; **121**: 298-305 [PMID: 18198187 DOI: 10.1242/jcs.021485]

67 **Shen L**, Weber CR, Turner JR. The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. *J Cell Biol* 2008; **181**: 683-695 [PMID: 18474622 DOI: 10.1083/jcb.200711165]

68 **Furuse M**, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. *J Cell Biol* 1994; **127**: 1617-1626 [PMID: 7798316 DOI: 10.1083/jcb.127.6.1617]

69 **Rajasekaran AK**, Hojo M, Huima T, Rodriguez-Boulan E. Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. *J Cell Biol* 1996; **132**: 451-463 [PMID: 8636221 DOI: 10.1083/jcb.132.3.451]

70 **Imamura Y**, Itoh M, Maeno Y, Tsukita S, Nagafuchi A. Functional domains of alpha-catenin required for the strong state of cadherin-based cell adhesion. *J Cell Biol* 1999; **144**: 1311-1322 [PMID: 10087272 DOI: 10.1083/jcb.144.6.1311]

71 **Arab JP**, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. *Hepatol Int* 2018; **12**: 24-33 [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x]

72 **Kim YS**, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. *Curr Gastroenterol Rep* 2010; **12**: 319-330 [PMID: 20703838 DOI: 10.1007/s11894-010-0131-2]

73 **Gassler N**. Paneth cells in intestinal physiology and pathophysiology. *World J Gastrointest Pathophysiol* 2017; **8**: 150-160 [PMID: 29184701 DOI: 10.4291/wjgp.v8.i4.150]

74 **Spadoni I**, Pietrelli A, Pesole G, Rescigno M. Gene expression profile of endothelial cells during perturbation of the gut vascular barrier. *Gut Microbes* 2016; **7**: 540-548 [PMID: 27723418 DOI: 10.1080/19490976.2016.1239681]

75 **Spadoni I**, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, Penna G, Dejana E, Rescigno M. A gut-vascular barrier controls the systemic dissemination of bacteria. *Science* 2015; **350**: 830-834 [PMID: 26564856 DOI: 10.1126/science.aad0135]

76 **von Olshausen G**, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, Zhang K, Odenthal M, Ringelhan M, Niessen CM, Protzer U. Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion. *Oncotarget* 2018; **9**: 33947-33960 [PMID: 30338037 DOI: 10.18632/oncotarget.26103]

77 **Wang Y**, Tong J, Chang B, Wang B, Zhang D, Wang B. Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins. *Mol Med Rep* 2014; **9**: 2352-2356 [PMID: 24718485 DOI: 10.3892/mmr.2014.2126]

78 **Tang Y**, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, Keshavarzian A. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. *Alcohol Clin Exp Res* 2008; **32**: 355-364 [PMID: 18162065 DOI: 10.1111/j.1530-0277.2007.00584.x]

79 **Rao R**. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. *Hepatology* 2009; **50**: 638-644 [PMID: 19575462 DOI: 10.1002/hep.23009]

80 **Basuroy S**, Sheth P, Kuppuswamy D, Balasubramanian S, Ray RM, Rao RK. Expression of kinase-inactive c-Src delays oxidative stress-induced disassembly and accelerates calcium-mediated reassembly of tight junctions in the Caco-2 cell monolayer. *J Biol Chem* 2003; **278**: 11916-11924 [PMID: 12547828 DOI: 10.1074/jbc.M211710200]

81 **Rao RK**, Basuroy S, Rao VU, Karnaky KJ Jr, Gupta A. Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress. *Biochem J* 2002; **368**: 471-481 [PMID: 12169098 DOI: 10.1042/bj20011804]

82 **Rao RK**, Li L, Baker RD, Baker SS, Gupta A. Glutathione oxidation and PTPase inhibition by hydrogen peroxide in Caco-2 cell monolayer. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G332-G340 [PMID: 10915642 DOI: 10.1152/ajpgi.2000.279.2.G332]

83 **Seth A**, Sheth P, Elias BC, Rao R. Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer. *J Biol Chem* 2007; **282**: 11487-11498 [PMID: 17298946 DOI: 10.1074/jbc.M610597200]

84 **Teltschik Z**, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. *Hepatology* 2012; **55**: 1154-1163 [PMID: 22095436 DOI: 10.1002/hep.24789]

85 **Al-Sadi R**, Ye D, Boivin M, Guo S, Hashimi M, Ereifej L, Ma TY. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. *PLoS One* 2014; **9**: e85345 [PMID: 24662742 DOI: 10.1371/journal.pone.0085345]

86 **Zolotarevsky Y**, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, Turner JR. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in *in vitro* models of intestinal disease. *Gastroenterology* 2002; **123**: 163-172 [PMID: 12105845 DOI: 10.1053/gast.2002.34235]

87 **Mankertz J**, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M, Schulzke JD. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. *J Cell Sci* 2000; **113**: 2085-2090 [PMID: 10806119 DOI: 10.1016/S0016-5085(00)84547-3]

88 **Wang F**, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. *Am J Pathol* 2005; **166**: 409-419 [PMID: 15681825 DOI: 10.1016/S0002-9440(10)62264-X]

89 **Bruewer M**, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. *J Immunol* 2003; **171**: 6164-6172 [PMID: 14634132 DOI: 10.4049/jimmunol.171.11.6164]

90 **Verbeke L**, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. *Am J Pathol* 2015; **185**: 409-419 [PMID: 25592258 DOI: 10.1016/j.ajpath.2014.10.009]

91 **Úbeda M**, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. *J Hepatol* 2016; **64**: 1049-1057 [PMID: 26723896 DOI: 10.1016/j.jhep.2015.12.010]

92 **Garcia-Tsao G**, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. *Best Pract Res Clin Gastroenterol* 2004; **18**: 353-372 [PMID: 15123075 DOI: 10.1016/j.bpg.2003.10.005]

93 **Reiberger T**, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. *J Hepatol* 2013; **58**: 911-921 [PMID: 23262249 DOI: 10.1016/j.jhep.2012.12.011]

94 **Geerts AM**, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, Demetter P, Lameire N, De Vos M, Colle I. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an *in vivo* study. *Liver Int* 2006; **26**: 889-898 [PMID: 16911473 DOI: 10.1111/j.1478-3231.2006.01308.x]

95 **Norman DA**, Atkins JM, Seelig LL Jr, Gomez-Sanchez C, Krejs GJ. Water and electrolyte movement and mucosal morphology in the jejunum of patients with portal hypertension. *Gastroenterology* 1980; **79**: 707-715 [PMID: 7409388 DOI: 10.1016/0016-5085(80)90249-8]

96 **Such J**, Guardiola JV, de Juan J, Casellas JA, Pascual S, Aparicio JR, Solá-Vera J, Pérez-Mateo M. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. *Eur J Gastroenterol Hepatol* 2002; **14**: 371-376 [PMID: 11943948 DOI: 10.1097/00042737-200204000-00006]

97 **Misra V**, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. *Am J Clin Pathol* 1997; **108**: 652-657 [PMID: 9384446 DOI: 10.1093/ajcp/108.6.652]

98 **Giofré MR**, Meduri G, Pallio S, Calandra S, Magnano A, Niceforo D, Cinquegrani M, di Leo V, Mazzon E, Sturniolo GC, Longo G, Fries W. Gastric permeability to sucrose is increased in portal hypertensive gastropathy. *Eur J Gastroenterol Hepatol* 2000; **12**: 529-533 [PMID: 10833096 DOI: 10.1097/00042737-200012050-00009]

99 **Di Leo V**, Venturi C, Baragiotta A, Martines D, Floreani A. Gastroduodenal and intestinal permeability in primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 2003; **15**: 967-973 [PMID: 12923368 DOI: 10.1097/00042737-200309000-00005]

100 **Cariello R**, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A, Miranda A, Portincasa P, Carbonara V, Palasciano G, Martorelli L, Esposito P, Cartenì M, Del Vecchio Blanco C, Loguercio C. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. *Dig Liver Dis* 2010; **42**: 200-204 [PMID: 19502117 DOI: 10.1016/j.dld.2009.05.001]

101 **Grønbaek H**, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. *Aliment Pharmacol Ther* 2012; **36**: 173-180 [PMID: 22591184 DOI: 10.1111/j.1365-2036.2012.05134.x]

102 **Sandahl TD**, McGrail R, Møller HJ, Reverter E, Møller S, Turon F, Hernández-Gea V, Bendtsen F, Vilstrup H, Garcia-Pagan JC, Grønbaek H. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. *Aliment Pharmacol Ther* 2016; **43**: 1222-1231 [PMID: 27061098 DOI: 10.1111/apt.13618]

103 **Weaver LK**, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, Guyre PM. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. *J Leukoc Biol* 2006; **80**: 26-35 [PMID: 16799153 DOI: 10.1189/jlb.1205756]

104 **Moestrup SK**, Møller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. *Ann Med* 2004; **36**: 347-354 [PMID: 15478309 DOI: 10.1080/07853890410033171]

105 **Holland-Fischer P**, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. *Gut* 2011; **60**: 1389-1393 [PMID: 21572121 DOI: 10.1136/gut.2010.234542]

106 **Berres ML**, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F, Strassburg CP, Trautwein C, Sauerbruch T, Wasmuth HE, Trebicka J. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. *J Hepatol* 2015; **62**: 332-339 [PMID: 25457205 DOI: 10.1016/j.jhep.2014.09.032]

107 **Berres ML**, Lehmann J, Jansen C, Görtzen J, Meyer C, Thomas D, Zimmermann HW, Kroy D, Schumacher F, Strassburg CP, Sauerbruch T, Trautwein C, Wasmuth HE, Trebicka J. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. *Liver Int* 2016; **36**: 386-394 [PMID: 26212075 DOI: 10.1111/liv.12922]

108 **Hsu SJ**, Tsai MH, Chang CC, Hsieh YH, Huang HC, Lee FY, Chuang CL, Hou MC, Lee SD. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. *Clin Sci (Lond)* 2018; **132**: 669-683 [PMID: 29449343 DOI: 10.1042/CS20171370]

109 **Payancé A**, Rautou PE. Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist. *Clin Sci (Lond)* 2018; **132**: 1341-1343 [PMID: 29954952 DOI: 10.1042/CS20180129]

110 **Nakamoto N**, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. *Nat Microbiol* 2019; **4**: 492-503 [PMID: 30643240 DOI: 10.1038/s41564-018-0333-1]

111 **Ridlon JM**, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. *Curr Opin Gastroenterol* 2014; **30**: 332-338 [PMID: 24625896 DOI: 10.1097/MOG.0000000000000057]

112 **Liao L**, Schneider KM, Galvez EJC, Frissen M, Marschall HU, Su H, Hatting M, Wahlström A, Haybaeck J, Puchas P, Mohs A, Peng J, Bergheim I, Nier A, Hennings J, Reißing J, Zimmermann HW, Longerich T, Strowig T, Liedtke C, Cubero FJ, Trautwein C. Intestinal dysbiosis augments liver disease progression *via* NLRP3 in a murine model of primary sclerosing cholangitis. *Gut* 2019; **68**: 1477-1492 [PMID: 30872395 DOI: 10.1136/gutjnl-2018-316670]

113 **Begley M**, Gahan CG, Hill C. The interaction between bacteria and bile. *FEMS Microbiol Rev* 2005; **29**: 625-651 [PMID: 16102595 DOI: 10.1016/j.femsre.2004.09.003]

114 **Coleman R**, Lowe PJ, Billington D. Membrane lipid composition and susceptibility to bile salt damage. *Biochim Biophys Acta* 1980; **599**: 294-300 [PMID: 7397151 DOI: 10.1016/0005-2736(80)90075-9]

115 **Heuman DM**, Bajaj RS, Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. *J Lipid Res* 1996; **37**: 562-573 [PMID: 8728319]

116 **Fujisawa T**, Mori M. Influence of bile salts on beta-glucuronidase activity of intestinal bacteria. *Lett Appl Microbiol* 1996; **22**: 271-274 [PMID: 8934784 DOI: 10.1111/j.1472-765X.1996.tb01159.x]

117 **Noh DO**, Gilliland SE. Influence of bile on cellular integrity and beta-galactosidase activity of Lactobacillus acidophilus. *J Dairy Sci* 1993; **76**: 1253-1259 [PMID: 8505417 DOI: 10.3168/jds.S0022-0302(93)77454-8]

118 **Leverrier P**, Dimova D, Pichereau V, Auffray Y, Boyaval P, Jan G. Susceptibility and adaptive response to bile salts in Propionibacterium freudenreichii: physiological and proteomic analysis. *Appl Environ Microbiol* 2003; **69**: 3809-3818 [PMID: 12839748 DOI: 10.1128/AEM.69.7.3809-3818.2003]

119 **de Valdez GF**, Martos G, Taranto MP, Lorca GL, Oliver G, de Ruiz Holgado AP. Influence of bile on beta-galactosidase activity and cell viability of Lactobacillus reuteri when subjected to freeze-drying. *J Dairy Sci* 1997; **80**: 1955-1958 [PMID: 9313134 DOI: 10.3168/jds.S0022-0302(97)76137-X]

120 **Chiang JY**. Bile acid metabolism and signaling. *Compr Physiol* 2013; **3**: 1191-1212 [PMID: 23897684 DOI: 10.1002/cphy.c120023]

121 **Arab JP**, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. *Hepatology* 2017; **65**: 350-362 [PMID: 27358174 DOI: 10.1002/hep.28709]

122 **Ridlon JM**, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. *Gut Microbes* 2013; **4**: 382-387 [PMID: 23851335 DOI: 10.4161/gmic.25723]

123 **Axelson M**, Sjövall J. Potential bile acid precursors in plasma--possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. *J Steroid Biochem* 1990; **36**: 631-640 [PMID: 2214780 DOI: 10.1016/0022-4731(90)90182-R]

124 **Stenman LK**, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. *Am J Physiol Gastrointest Liver Physiol* 2013; **304**: G227-G234 [PMID: 23203158 DOI: 10.1152/ajpgi.00267.2012]

125 **Stenman LK**, Holma R, Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. *World J Gastroenterol* 2012; **18**: 923-929 [PMID: 22408351 DOI: 10.3748/wjg.v18.i9.923]

126 **Dikopoulos N**, Weidenbach H, Adler G, Schmid RM. Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II. *Eur J Clin Invest* 2003; **33**: 58-64 [PMID: 12492453 DOI: 10.1046/j.1365-2362.2003.01079.x]

127 **Inagaki T**, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A* 2006; **103**: 3920-3925 [PMID: 16473946 DOI: 10.1073/pnas.0509592103]

128 **Edwards PA**, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. *J Lipid Res* 2002; **43**: 2-12 [PMID: 11792716]

129 **Bookout AL**, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. *Cell* 2006; **126**: 789-799 [PMID: 16923397 DOI: 10.1016/j.cell.2006.06.049]

130 **Ding JW**, Andersson R, Soltesz V, Willén R, Bengmark S. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. *Eur Surg Res* 1993; **25**: 11-19 [PMID: 8482301 DOI: 10.1159/000129252]

131 **Lorenzo-Zúñiga V**, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. *Hepatology* 2003; **37**: 551-557 [PMID: 12601352 DOI: 10.1053/jhep.2003.50116]

132 **Inagaki T**, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* 2005; **2**: 217-225 [PMID: 16213224 DOI: 10.1016/j.cmet.2005.09.001]

133 **Kliewer SA**, Mangelsdorf DJ. Bile Acids as Hormones: The FXR-FGF15/19 Pathway. *Dig Dis* 2015; **33**: 327-331 [PMID: 26045265 DOI: 10.1159/000371670]

134 **Holt JA**, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. *Genes Dev* 2003; **17**: 1581-1591 [PMID: 12815072 DOI: 10.1101/gad.1083503]

135 **Kim I**, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. *J Lipid Res* 2007; **48**: 2664-2672 [PMID: 17720959 DOI: 10.1194/jlr.M700330-JLR200]

136 **Goodwin B**, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell* 2000; **6**: 517-526 [PMID: 11030332 DOI: 10.1016/S1097-2765(00)00051-4]

137 **Tomlinson E**, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. *Endocrinology* 2002; **143**: 1741-1747 [PMID: 11956156 DOI: 10.1210/endo.143.5.8850]

138 **Byun S**, Kim DH, Ryerson D, Kim YC, Sun H, Kong B, Yau P, Guo G, Xu HE, Kemper B, Kemper JK. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. *Nat Commun* 2018; **9**: 2590 [PMID: 29968724 DOI: 10.1038/s41467-018-04697-5]

139 **Wunsch E**, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. *Sci Rep* 2015; **5**: 13462 [PMID: 26293907 DOI: 10.1038/srep13462]

140 **Lutz P**, Krämer B, Kaczmarek DJ, Hübner MP, Langhans B, Appenrodt B, Lammert F, Nattermann J, Hoerauf A, Strassburg CP, Spengler U, Nischalke HD. A variant in the nuclear dot protein 52kDa gene increases the risk for spontaneous bacterial peritonitis in patients with alcoholic liver cirrhosis. *Dig Liver Dis* 2016; **48**: 62-68 [PMID: 26493630 DOI: 10.1016/j.dld.2015.09.011]

141 **Nischalke HD**, Berger C, Aldenhoff K, Thyssen L, Gentemann M, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U, Appenrodt B. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. *J Hepatol* 2011; **55**: 1010-1016 [PMID: 21356257 DOI: 10.1016/j.jhep.2011.02.022]

142 **Appenrodt B**, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. *Hepatology* 2010; **51**: 1327-1333 [PMID: 20087966 DOI: 10.1002/hep.23440]

143 **Bruns T**, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl J, Schölmerich J, Wiest R, Stallmach A. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. *Liver Int* 2012; **32**: 223-230 [PMID: 21745302 DOI: 10.1111/j.1478-3231.2011.02561.x]

144 **Caruso R**, Warner N, Inohara N, Núñez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. *Immunity* 2014; **41**: 898-908 [PMID: 25526305 DOI: 10.1016/j.immuni.2014.12.010]

145 **Harputluoglu MM**, Dertli R, Otlu B, Demirel U, Yener O, Bilgic Y, Erdogan MA, Atayan Y, Cagin YF. Nucleotide-Binding Oligomerization Domain-Containing Protein 2 Variants in Patients with Spontaneous Bacterial Peritonitis. *Dig Dis Sci* 2016; **61**: 1545-1552 [PMID: 26725065 DOI: 10.1007/s10620-015-4024-y]

146 **Reichert MC**, Ripoll C, Casper M, Greinert R, Vandieken E, Grünhage F, Appenrodt B, Zipprich A, Lammert F. Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. *Clin Transl Gastroenterol* 2019; **10**: e00002 [PMID: 30702490 DOI: 10.14309/ctg.0000000000000002]

147 **Lutz P**, Berger C, Langhans B, Grünhage F, Appenrodt B, Nattermann J, Lammert F, Hoerauf A, Sauerbruch T, Strassburg CP, Spengler U, Nischalke HD. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. *Dig Liver Dis* 2014; **46**: 1047-1050 [PMID: 25086996 DOI: 10.1016/j.dld.2014.07.008]

148 **Van Mil SW**, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. *Gastroenterology* 2007; **133**: 507-516 [PMID: 17681172 DOI: 10.1053/j.gastro.2007.05.015]

149 **Marzolini C**, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. *Mol Endocrinol* 2007; **21**: 1769-1780 [PMID: 17519356 DOI: 10.1210/me.2007-0025]

150 **Semmler G**, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Bauer D, Pinter M, Ferenci P, Trauner M, Mandorfer M, Reiberger T. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. *J Gastroenterol Hepatol* 2019; [PMID: 31062417 DOI: 10.1111/jgh.14700]

151 **Sorribas M**, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. *J Hepatol* 2019; [PMID: 31295531 DOI: 10.1016/j.jhep.2019.06.017]

152 **Vorobioff J**, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, Audano M, Tanno H, Lerner E, Passamonti M. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. *Gastroenterology* 1996; **111**: 701-709 [PMID: 8780575 DOI: 10.1053/gast.1996.v111.pm8780575]

153 **Lackner C**, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, Haas J, Berghold A, Bataller R, Stauber RE. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. *J Hepatol* 2017; **66**: 610-618 [PMID: 27894795 DOI: 10.1016/j.jhep.2016.11.011]

154 **Verrill C**, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. *Addiction* 2009; **104**: 768-774 [PMID: 19344445 DOI: 10.1111/j.1360-0443.2009.02521.x]

155 **Vilar-Gomez E**, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 2015; **149**: 367-378.e5 [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005]

156 **Schwabl P**, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther* 2017; **45**: 139-149 [PMID: 27910154 DOI: 10.1111/apt.13844]

157 **Mandorfer M**, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *J Hepatol* 2016; **65**: 692-699 [PMID: 27242316 DOI: 10.1016/j.jhep.2016.05.027]

158 **Piñero F**, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M; LALREAN. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. *Liver Int* 2019; **39**: 1033-1043 [PMID: 30636361 DOI: 10.1111/liv.14041]

159 **Lens S**, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. *Gastroenterology* 2017; **153**: 1273-1283.e1 [PMID: 28734831 DOI: 10.1053/j.gastro.2017.07.016]

160 **Wiest R**, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. *J Hepatol* 2017; **67**: 1084-1103 [PMID: 28526488 DOI: 10.1016/j.jhep.2017.05.007]

161 **Chu H**, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. *Liver Res* 2018; **2**: 43-51 [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005]

162 **Reiberger T**, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). *Wien Klin Wochenschr* 2017; **129**: 135-158 [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3]

163 **Pfisterer N**, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. *Aliment Pharmacol Ther* 2018; **47**: 966-979 [PMID: 29388229 DOI: 10.1111/apt.14485]

164 **Reiberger T**, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. *Gut* 2013; **62**: 1634-1641 [PMID: 23250049 DOI: 10.1136/gutjnl-2012-304038]

165 **Mookerjee RP**, Pavesi M, Thomsen KL, Mehta G, Macnaughtan J, Bendtsen F, Coenraad M, Sperl J, Gines P, Moreau R, Arroyo V, Jalan R; CANONIC Study Investigators of the EASL-CLIF Consortium. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. *J Hepatol* 2016; **64**: 574-582 [PMID: 26519600 DOI: 10.1016/j.jhep.2015.10.018]

166 **Pérez-Paramo M**, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. *Hepatology* 2000; **31**: 43-48 [PMID: 10613726 DOI: 10.1002/hep.510310109]

167 **Fernández J**, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. *Gastroenterology* 2007; **133**: 818-824 [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065]

168 **Fernández J**, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin *vs* ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. *Gastroenterology* 2006; **131**: 1049-1056 [PMID: 17030175 DOI: 10.1053/j.gastro.2006.07.010]

169 **Casper M**, Mengel M, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grünhage F, Lammert F; INCA trial group. The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. *Trials* 2015; **16**: 83 [PMID: 25887140 DOI: 10.1186/s13063-015-0594-4]

170 **Kemp W**, Colman J, Thompson K, Madan A, Vincent M, Chin-Dusting J, Kompa A, Krum H, Roberts S. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. *Liver Int* 2009; **29**: 427-433 [PMID: 18673434 DOI: 10.1111/j.1478-3231.2008.01850.x]

171 **Rasaratnam B**, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. *Ann Intern Med* 2003; **139**: 186-193 [PMID: 12899586 DOI: 10.7326/0003-4819-139-3-200308050-00008]

172 **Kalambokis GN**, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsianos EV. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. *Clin Gastroenterol Hepatol* 2012; **10**: 815-818 [PMID: 22391344 DOI: 10.1016/j.cgh.2012.02.025]

173 **Vlachogiannakos J**, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. *J Gastroenterol Hepatol* 2013; **28**: 450-455 [PMID: 23216382 DOI: 10.1111/jgh.12070]

174 **Kimer N**, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. *J Gastroenterol Hepatol* 2018; **33**: 307-314 [PMID: 28671712 DOI: 10.1111/jgh.13852]

175 **Kimer N**, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. *Hepatology* 2017; **65**: 592-603 [PMID: 27775818 DOI: 10.1002/hep.28898]

176 **Madsen BS**, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, Krag A. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. *Trials* 2018; **19**: 143 [PMID: 29482588 DOI: 10.1186/s13063-018-2523-9]

177 **Tsai CF**, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. *Gastroenterology* 2017; **152**: 134-141 [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007]

178 **Dam G**, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. *Hepatology* 2016; **64**: 1265-1272 [PMID: 27474889 DOI: 10.1002/hep.28737]

179 **Merli M**, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. *Liver Int* 2015; **35**: 362-369 [PMID: 24836902 DOI: 10.1111/liv.12593]

180 **Bajaj JS**, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, Hylemon PB, White MB, Daita K, Noble NA, Sikaroodi M, Williams R, Crossey MM, Taylor-Robinson SD, Gillevet PM. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. *Am J Physiol Gastrointest Liver Physiol* 2014; **307**: G951-G957 [PMID: 25258407 DOI: 10.1152/ajpgi.00268.2014]

181 **Schaap FG**, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 55-67 [PMID: 23982684 DOI: 10.1038/nrgastro.2013.151]

182 **Verbeke L**, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Sci Rep* 2016; **6**: 33453 [PMID: 27634375 DOI: 10.1038/srep33453]

183 **Neuschwander-Tetri BA**, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015; **385**: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4]

184 **Nevens F**, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *N Engl J Med* 2016; **375**: 631-643 [PMID: 27532829 DOI: 10.1056/NEJMoa1509840]

185 **Kowdley KV**, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. *Hepatology* 2018; **67**: 1890-1902 [PMID: 29023915 DOI: 10.1002/hep.29569]

186 **Nicholes K**, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. *Am J Pathol* 2002; **160**: 2295-2307 [PMID: 12057932 DOI: 10.1016/s0002-9440(10)61177-7]

187 **Younossi** **Z**, Ratziu V, Loomba R, Rinella M, Anstee Q, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome P, Sheridan D, Trotter J, Knapple W, Lawitz E, Kowdley K, Montano-Loza A, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal A, GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. *J Hepatol* 2019; **70**: e5 [DOI: 10.1016/S0618-8278(19)30006-4]

188 **Mookerjee** **R**, Rosselli M, Pieri G, Beecher-Jones T, Hooshmand-Rad R, Chouhan M, Mehta G, Jalan R, Shapiro D. O15 Effects of the Fxr Agonist Obeticholic Acid on Hepatic Venous Pressure Gradient (HVPG) in Alcoholic Cirrhosis: A Proof of Concept Phase 2a Study. *J Hepatol* 2014; **60**: S7-S8 [DOI: 10.1016/S0168-8278(14)60017-9]

189 **Fang S**, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. *Nat Med* 2015; **21**: 159-165 [PMID: 25559344 DOI: 10.1038/nm.3760]

190 **Hartmann P**, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. *Hepatology* 2018; **67**: 2150-2166 [PMID: 29159825 DOI: 10.1002/hep.29676]

191 **Gadaleta RM**, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011; **60**: 463-472 [PMID: 21242261 DOI: 10.1136/gut.2010.212159]

192 **Schwabl P**, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. *J Hepatol* 2017; **66**: 724-733 [PMID: 27993716 DOI: 10.1016/j.jhep.2016.12.005]

193 **Hirschfield GM**, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. *J Hepatol* 2019; **70**: 483-493 [PMID: 30414864 DOI: 10.1016/j.jhep.2018.10.035]

194 **Goto T**, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. *Sci Rep* 2018; **8**: 8157 [PMID: 29802399 DOI: 10.1038/s41598-018-26383-8]

195 **Briand F**, Brousseau E, Quinsat M, Burcelin R, Sulpice T. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model. *Eur J Pharmacol* 2018; **818**: 449-456 [PMID: 29155143 DOI: 10.1016/j.ejphar.2017.11.021]

196 **Maneschi E**, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I, Comeglio P, Sarchielli E, Calcagno A, Mazzanti B, Vettor R, Vannelli GB, Adorini L, Maggi M. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. *J Endocrinol* 2013; **218**: 215-231 [PMID: 23750014 DOI: 10.1530/JOE-13-0109]

197 **Friedman ES**, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. *Gastroenterology* 2018; **155**: 1741-1752.e5 [PMID: 30144429 DOI: 10.1053/j.gastro.2018.08.022]

198 **Pathak P**, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. *Hepatology* 2018; **68**: 1574-1588 [PMID: 29486523 DOI: 10.1002/hep.29857]

**P-Reviewer:** Abid S, Orci LA, Russo E

**S-Editor:** Tang JZ **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Austria

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1** **An impaired mucosal epithelial barrier integrity facilitates bacterial translocation and is regulated by farnesoid X receptor-dependent mechanisms.** Increased systemic inflammation in cirrhotic patients as compared to healthy subjects is considered to be associated with intestinal dysbiosis leading to translocation of pathogens- or derived pathogen-associated molecular patterns and danger-associated molecular patterns into the portal circulation, which is further facilitated by an impaired intestinal barrier. Farnesoid X receptor (FXR) activation in ileum enhances the expression of fibroblast growth factor 15 (mice) or 19 (humans) *via* binding to response elements in the nucleus. FXR activation leads to upregulation of tight junction proteins and decrease of bacterial translocation. FXR: Farnesoid X receptor; IgA: Immunoglobulin A; RXRα: Retinoid X receptor; FGF: Fibroblast growth factor; LPS: Lipopolysaccharide; TJ: Tight junction.



**Figure 2** **Farnesoid X receptor-fibroblast growth factor 19 signaling between gut and liver regulates bile acid homeostasis and impacts on mucosal barrier function.** Bacterial translocation triggers fibrosis and hepatic inflammation *via* activation of hepatic stellate cells and liver-resident macrophages. Fibroblast growth factor (FGF) 19 binds to FGF receptor 4 on hepatocytes which subsequently suppresses the expression of CYP7A1. FGF19 is upregulated postprandially and influences farnesoid X receptor-dependent metabolic pathways involved in gluconeogenesis, protein synthesis, insulin sensitivity and lipid profile. Kupffer cells and monocyte-derived macrophages produce cytokines and chemotactic molecules in response to liver injury. Recognition of lipopolysaccharide by Toll-like receptor 4 on macrophages and Kupffer cells results in activation of the NFκ-B-regulated inflammasome and increases tumor necrosis factor-α synthesis. In the continuous presence of injury, pathogen-associated molecular patterns and/or danger-associated molecular patterns, these cells create a proinflammatory environment that finally cause hepatocyte injury and fibrosis *via* hepatic stellate cell stimulation that results in production of collagen and α-smooth muscle actin. FXR: Farnesoid X receptor; RXRα: Retinoid X receptor; BSEP: Bile salt export pump; FGF: Fibroblast growth factor; FGFR4: Fibroblast growth factor receptor 4; LPS: Lipopolysaccharide; α-SMA: α smooth muscle actin; TNF: Tumor necrosis factor; IL: Interleukin; HSC: Hepatic stellate cell; LSEC: Liver sinusoidal endothelial cell; TLR: Toll-like receptor; PAMPs: Pathogen-associated molecular patterns; α-SMA: α-smooth muscle actin.

**Table 1** **Farnesoid X receptor-targeting therapies in liver disease: Experimental *vs* clinical evidence**

|  |  |  |  |
| --- | --- | --- | --- |
| **Location** | **Target** | **Experimental evidence** | **Clinical evidence** |
| Liver | Metabolism/inflammation | OCA/NASH/mouse: Decreased hepatocyte apoptosis and less fibrosis; similar steatosis[[194](#_ENREF_194)]  OCA/NASH/hamster: Higher LDL and lower HDL[[195](#_ENREF_195)]  OCA/NAFLD/rabbit: Decreased steatosis, inflammation, insulin resistance and improved lipid profile[[196](#_ENREF_196)] | OCA/NASH/NCT01265498: Improved histological features; 20% pruritus, impaired lipid profile[[183](#_ENREF_183)]  OCA/PBC/NCT01473524: Improved biochemical laboratory values; frequent pruritus[[184](#_ENREF_184),[185](#_ENREF_185)]  OCA/PSC/NCT02177136: Completed; statistical results pending; PEP: Change of ALP levels as compared to BL |
|  | Fibrosis/PHT | PX20606/CCl4/rat: Reduced fibrosis, PP, and sinusoidal remodeling[[192](#_ENREF_192)]  OCA/TAA/rat: Reduced fibrosis, PP, hepatic inflammation[[182](#_ENREF_182)] | OCA/NASH/NCT02548351: Recruiting; PEP: 1 stage of liver fibrosis improvement; NASH resolution  OCA/PBC/NCT02308111: Recruiting; PEP: Death, OLT; MELD ≥ 15; decompensation  NGM282/PSC/NCT02704364: reduced fibrosis biomarkers[[193](#_ENREF_193)]  OCA/ALD/PESTO: PEP: Lower HVPG after 7 d of treatment by 15% or more, or HVPG < 12 mmHg[[188](#_ENREF_188)] |
| Gut | Microbiome | OCA/Healthy/mouse: lower endogenous BA levels; elevated Firmicutes in small intestine[[197](#_ENREF_197)]  Fexaramine/NAFLD/mouse: Microbiome changes induce different BA profile; GLP-1 signaling improves insulin sensitivity[[198](#_ENREF_198" \o "Pathak, 2018 #339)] | OCA/Healthy/NCT01933503: Reversible changes in gram-positive bacterial strains[[197](#_ENREF_197)] |
|  | Intestinal barrier | OCA/BDL/rat: Upregulation of TJ proteins, decrease of intestinal inflammation and BT[[90](#_ENREF_90)]  OCA/CCl4/rat: Upregulation of antimicrobial peptides, TJ proteins; reduced BT and liver fibrosis[[91](#_ENREF_91)]  GW4064/BDL/mouse: Upregulation of enteroprotective genes and improvement of barrier function[[127](#_ENREF_127)]  Fexaramine/ALD/mouse: Improvement of intestinal barrier, lipid metabolism and alcohol-induced liver injury[[190](#_ENREF_190)]  OCA + Fexaramine/PPVL + BDL + CCl4/mouse: reduction of BT; OCA: Improvement of muco-epithelial and gut-vascular barrier; Fexaramine: Improvement of muco-epithelial but no effect on gut-vascular barrier[[151](#_ENREF_151)] | No human data available |
|  | Metabolism/inflammation | Fexaramine/NAFLD/mouse: Amelioration of metabolic syndrome, induction of FGF15, decreased insulin resistance[[189](#_ENREF_189)]  OCA/IBD/mouse: Decreased intestinal inflammation and permeability[[191](#_ENREF_191)] | No human data available |

OCA: Obeticholic acid; NASH: Non-alcoholic steatohepatitis; LDL: Low density lipoprotein; HDL: High density lipoprotein; NAFLD: Non-alcoholic fatty liver disease; NCT: National clinical trial identifier; PEP: Primary efficacy endpoint; ALP: Alkaline phosphatase; BL: Baseline; CCl4: Carbon tetrachloride; PP: Portal pressure; TAA: Thioacetamide; OLT: Orthotopic liver transplantation; MELD: Model for end-stage liver disease; ALD: Alcoholic liver disease; HVPG: Hepatic venous pressure gradient; BA: Bile acid; GLP-1: Glucagon like peptide 1; TJ: Tight junction; BT: Bacterial translocation; BDL: Bile duct ligation; FGF15: Fibroblast growth factor 15; IBD: Inflammatory bowel disease.